Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through the inhibition of efflux transporters BCRP and MRP2

26Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Although hepatoprotective properties of silybin are well documented, the clinical therapeutic efficacy is limited by its low bioavailability due to absorption rates, extensive phase II metabolism, and biliary excretion. As our previous study indicated that metabolic enzymes may have limited effects on the pharmacokinetic (PK) behavior of silymarin, here, we intended to increase the oral bioavailability and bio-efficacy of silybin through the inhibition of active efflux. In Caco-2 and transfected MDCKII cell models, flavone baicalein significantly inhibited the efflux of silybin as a BCRP and MRP2 inhibitor. In addition, baicalein reduced the biliary excretion index (BEI) and biliary clearance of silybin conjugates in the sandwich-cultured rat hepatocyte (SCH) model, indicating the inhibition of baicalein in biliary excretion of conjugated silybin metabolites. PK study demonstrated that baicalein significantly increased the area under the curve (AUC) and Cmax of silybin and its conjugates, suggesting enhanced absorption in vivo. Moreover, coadministration of silybin with baicalein boosted the liver protective, antioxidant, and anti-inflammatory effects of silybin in the carbon tetrachloride (CCl4)-induced liver injury model in comparison with silybin given alone. In summary, efflux transporters play a critical role in the low bioavailability of silybin, while inhibition of breast cancer resistance protein (BCRP) and multi-drug resistance protein 2 (MRP2) by baicalein can significantly increase the absorption and bio-efficacy of silybin, which provides a new combination therapeutic approach for the treatment of chronic liver diseases.

References Powered by Scopus

Membrane transporters in drug development

2852Citations
N/AReaders
Get full text

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview

1294Citations
N/AReaders
Get full text

Blood sample collection in small laboratory animals

777Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Metabolism, transport and drug–drug interactions of silymarin

66Citations
N/AReaders
Get full text

Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin

49Citations
N/AReaders
Get full text

Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications

46Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Xu, P., Zhou, H., Li, Y. Z., Yuan, Z. W., Liu, C. X., Liu, L., & Xie, Y. (2018). Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through the inhibition of efflux transporters BCRP and MRP2. Frontiers in Pharmacology, 9(OCT). https://doi.org/10.3389/fphar.2018.01115

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

57%

Researcher 4

29%

Professor / Associate Prof. 2

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

40%

Pharmacology, Toxicology and Pharmaceut... 5

33%

Chemistry 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free